Gan & Lee Pharmaceuticals.

This study tests a new insulin called GZR33 against a standard insulin (Tresiba) in 350 adults with type 2 diabetes whose blood sugar is not well controlled by pills alone. The main goal is to see if GZR33 lowers blood sugar levels (HbA1c) as well or better after 26 weeks. Partic…

This early-stage study tests a new drug called GLR2037 in about 65 men with metastatic prostate cancer that has spread to bones or soft tissue. The main goal is to check the drug's safety and how the body processes it. Participants must have already tried hormone therapy and have…

This study tests a new injectable medicine, GZR101-80, for people with type 2 diabetes that is not well controlled by current pills or basal insulin. About 345 adults will receive the drug for 16 weeks to see if it lowers blood sugar and HbA1c safely. The goal is better daily con…

This study tests an injection called GZR18 in 140 obese adults with moderate to severe obstructive sleep apnea who cannot or will not use a CPAP machine. The main goal is to see if the drug reduces breathing pauses during sleep and helps with weight loss over 52 weeks. Participan…

This study tests an injectable drug called GZR18 in 140 obese adults with moderate-to-severe obstructive sleep apnea who already use a breathing machine (PAP). The goal is to see if the drug improves breathing during sleep, reduces symptoms, and helps with weight loss compared to…

This study checks if a new drug called GLR1044 is similar to the approved drug Dupixent. It involves 198 healthy Chinese men who get a single shot of either the new drug or Dupixent. The goal is to compare how the body processes each drug, not to treat any disease. Participants w…